Undercarboxylated osteocalcin and development of a method to determine vitamin K status

Lori J Sokoll, M. E. O'Brien, M. E. Camilo, J. A. Sadowski

Research output: Contribution to journalArticle

Abstract

We developed a RIA involving a polyclonal antibody against bovine osteocalcin, which has a carboxy-terminal epitope. Although the antibody recognizes both native and descarboxy osteocalcin, the two forms of osteocalcin were differentiated by adsorption to barium sulfate, taking advantage of the calcium-binding properties of the vitamin K-dependent gla domain. To test the clinical application of undercarboxylated osteocalcin, we examined the effect of minidose warfarin on this measure in nine healthy subjects, ages 60 to 80 years. The percentage of undercarboxylated osteocalcin increased by 170% ± 36% (mean ± SE) after 7 days of treatment with warfarin, 1 mg/day. The effectiveness of undercarboxylated osteocalcin as a sensitive measure of vitamin K nutritional status was further established when concentrations dropped to 17% ± 14% below baseline with 2 days of repletion with vitamin K1, 5 mg/day, during which prothrombin times did not leave the normal range.

Original languageEnglish (US)
Pages (from-to)1121-1128
Number of pages8
JournalClinical Chemistry
Volume41
Issue number8
StatePublished - 1995

Fingerprint

Vitamin K
Osteocalcin
Warfarin
Barium Sulfate
Vitamin K 1
Antibodies
Prothrombin Time
Prothrombin
Nutritional Status
Adsorption
Epitopes
Healthy Volunteers
Reference Values
Calcium

Keywords

  • anticoagulants
  • nutritional status
  • radioimmunoassay
  • warfarin

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Sokoll, L. J., O'Brien, M. E., Camilo, M. E., & Sadowski, J. A. (1995). Undercarboxylated osteocalcin and development of a method to determine vitamin K status. Clinical Chemistry, 41(8), 1121-1128.

Undercarboxylated osteocalcin and development of a method to determine vitamin K status. / Sokoll, Lori J; O'Brien, M. E.; Camilo, M. E.; Sadowski, J. A.

In: Clinical Chemistry, Vol. 41, No. 8, 1995, p. 1121-1128.

Research output: Contribution to journalArticle

Sokoll, LJ, O'Brien, ME, Camilo, ME & Sadowski, JA 1995, 'Undercarboxylated osteocalcin and development of a method to determine vitamin K status', Clinical Chemistry, vol. 41, no. 8, pp. 1121-1128.
Sokoll, Lori J ; O'Brien, M. E. ; Camilo, M. E. ; Sadowski, J. A. / Undercarboxylated osteocalcin and development of a method to determine vitamin K status. In: Clinical Chemistry. 1995 ; Vol. 41, No. 8. pp. 1121-1128.
@article{4391edc889a74cb49e04a5ca705b881b,
title = "Undercarboxylated osteocalcin and development of a method to determine vitamin K status",
abstract = "We developed a RIA involving a polyclonal antibody against bovine osteocalcin, which has a carboxy-terminal epitope. Although the antibody recognizes both native and descarboxy osteocalcin, the two forms of osteocalcin were differentiated by adsorption to barium sulfate, taking advantage of the calcium-binding properties of the vitamin K-dependent gla domain. To test the clinical application of undercarboxylated osteocalcin, we examined the effect of minidose warfarin on this measure in nine healthy subjects, ages 60 to 80 years. The percentage of undercarboxylated osteocalcin increased by 170{\%} ± 36{\%} (mean ± SE) after 7 days of treatment with warfarin, 1 mg/day. The effectiveness of undercarboxylated osteocalcin as a sensitive measure of vitamin K nutritional status was further established when concentrations dropped to 17{\%} ± 14{\%} below baseline with 2 days of repletion with vitamin K1, 5 mg/day, during which prothrombin times did not leave the normal range.",
keywords = "anticoagulants, nutritional status, radioimmunoassay, warfarin",
author = "Sokoll, {Lori J} and O'Brien, {M. E.} and Camilo, {M. E.} and Sadowski, {J. A.}",
year = "1995",
language = "English (US)",
volume = "41",
pages = "1121--1128",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "8",

}

TY - JOUR

T1 - Undercarboxylated osteocalcin and development of a method to determine vitamin K status

AU - Sokoll, Lori J

AU - O'Brien, M. E.

AU - Camilo, M. E.

AU - Sadowski, J. A.

PY - 1995

Y1 - 1995

N2 - We developed a RIA involving a polyclonal antibody against bovine osteocalcin, which has a carboxy-terminal epitope. Although the antibody recognizes both native and descarboxy osteocalcin, the two forms of osteocalcin were differentiated by adsorption to barium sulfate, taking advantage of the calcium-binding properties of the vitamin K-dependent gla domain. To test the clinical application of undercarboxylated osteocalcin, we examined the effect of minidose warfarin on this measure in nine healthy subjects, ages 60 to 80 years. The percentage of undercarboxylated osteocalcin increased by 170% ± 36% (mean ± SE) after 7 days of treatment with warfarin, 1 mg/day. The effectiveness of undercarboxylated osteocalcin as a sensitive measure of vitamin K nutritional status was further established when concentrations dropped to 17% ± 14% below baseline with 2 days of repletion with vitamin K1, 5 mg/day, during which prothrombin times did not leave the normal range.

AB - We developed a RIA involving a polyclonal antibody against bovine osteocalcin, which has a carboxy-terminal epitope. Although the antibody recognizes both native and descarboxy osteocalcin, the two forms of osteocalcin were differentiated by adsorption to barium sulfate, taking advantage of the calcium-binding properties of the vitamin K-dependent gla domain. To test the clinical application of undercarboxylated osteocalcin, we examined the effect of minidose warfarin on this measure in nine healthy subjects, ages 60 to 80 years. The percentage of undercarboxylated osteocalcin increased by 170% ± 36% (mean ± SE) after 7 days of treatment with warfarin, 1 mg/day. The effectiveness of undercarboxylated osteocalcin as a sensitive measure of vitamin K nutritional status was further established when concentrations dropped to 17% ± 14% below baseline with 2 days of repletion with vitamin K1, 5 mg/day, during which prothrombin times did not leave the normal range.

KW - anticoagulants

KW - nutritional status

KW - radioimmunoassay

KW - warfarin

UR - http://www.scopus.com/inward/record.url?scp=0029126853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029126853&partnerID=8YFLogxK

M3 - Article

C2 - 7628086

AN - SCOPUS:0029126853

VL - 41

SP - 1121

EP - 1128

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 8

ER -